Intrapartum GBS screening and antibiotic prophylaxis: A European consensus conference

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 28, Issue 7, 2015, Pages 766-782

  Di Renzo, G C ^a   Melin, P ^b   Berardi, A ^c   Blennow, M ^d   Carbonell Estrany, X ^e   Donzelli, G P ^f   Hakansson, S ^g   Hod, M ^h   Hughes, R ⁱ   Kurtzer, M ^j   Poyart, C ^k   Shinwell, E ^l   Stray Pedersen, B ^m   Wielgos, M ⁿ   El Helali, N ^o  

^a Santa Maria della Misericordia University Hospital   (Italy)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF FLORENCE   (Italy)

^g UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ NHS LOTHIAN   (United Kingdom)

^j Perinatal Medical Center Group of Companies Mother and Child   (Russian Federation)

^k Institut Cochin   (France)

^l BAR ILAN UNIVERSITY   (Israel)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

ⁿ MEDICAL UNIVERSITY OF WARSAW   (Poland)

^o Hôpital Paris Saint Joseph   (France)

more..

Author keywords

Antibiotic prophylaxis; GBS screening; Group B streptococcus

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEPHALOSPORIN; CLINDAMYCIN; ERYTHROMYCIN; PENICILLIN G; VANCOMYCIN; STREPTOCOCCUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; CONSENSUS; DRUG INDICATION; EUROPE; FEMALE; GROUP B STREPTOCOCCAL INFECTION; HEALTH CARE PLANNING; HUMAN; INCIDENCE; INTRAPARTUM CARE; MEDICAL DECISION MAKING; NEWBORN INFECTION; NONHUMAN; PRACTICE GUIDELINE; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; PRIORITY JOURNAL; RAPID TEST; REVIEW; RISK ASSESSMENT; SCREENING TEST; STREPTOCOCCUS AGALACTIAE; VACCINATION; CONSENSUS DEVELOPMENT; ISOLATION AND PURIFICATION; MASS SCREENING; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; PREVENTION AND CONTROL; PROCEDURES; STREPTOCOCCAL INFECTIONS; TRANSMISSION; VERTICAL TRANSMISSION;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; EUROPE; FEMALE; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE;

EID: 84930910594     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2014.934804     Document Type: Review

References (137)

1. Centers for Disease Control and Prevention. Prevention of perinatal Group B streptococcal disease. MMWR 2002;51:1-22.
2. Melin P, Verschraegen G, Mahieu L, et al. Towards a Belgian consensus for prevention of perinatal group B streptococcal disease. Indian J Med Res 2004;119:197-200.
3. Lopez Sastre JB, Fernandez Colomer B, Coto Cotallo GD, et al. Trends in the epidemiology of neonatal sepsis of vertical transmission in the era of group B streptococcal prevention. Acta Paediatr 2005;94:451-7.
4. Centers for Disease Control and Prevention. Prevention of perinatal Group B streptococcal disease. Revised guidelines from CDC, 2010. MMWR 2010;59:No.RR-10:1-32.
5. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976;294:753-6.
6. Baker C. Group B streptococcal infections. In: Stevens DL, Kaplan EL, eds. Streptococcal infections. New York (NY): Oxford University Press; 2000:222-37.
7. Centers for Disease Control and Prevention. Perinatal group B streptococcal disease after universal screening recommendations United States 2003-2005. MMWR Morb Mortal Wkly Rep 2007;56:701-5.
8. Heath PT, Schuchat A. Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol 2007;21:411-24.
9. Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive group B streptococcal disease in non pregnant adults, 1990-2007. CID 2009;49:85-92.
10. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20.
11. Nizet V, Ferrieri P, Rubens CE. Molecular pathogenesis of group B streptococcal disease in newborns. In: Stevens DL, Kaplan EL, eds. Streptococcal infections. New York: Oxford University Press, 2000: 180-221.
12. Trijbels-Smeulders MAJM, Kolee LAA, Adriaanse AH, et al. Neonatal group B streptococcal infection: incidence and strategies for prevention in Europe. Pediatr Infect Dis J 2004;23:172-3.
13. Edmond KE, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012;379:547-56.
14. Melin P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies. Clin Microbiol Infect 2011;17:1294-303.
15. Jordan HT, Farley MM, Craig A, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: A multistate, population-based analysis. Pediatr Infect Dis J 2008;27:1057-64.
16. Verani JR, Schrag SJ. Group B streptococcal disease in infants: progress in prevention and continued challenges. Clin Perinatol 2010;37:375-92.
17. Anthony BF, Okada DM, Hobel CJ. Epidemiology of the group B streptococcus: maternal and nosocomial sources for infant acquisitions. J Pediatr 1979;95:431-6.
18. Boyer KM, Gotoff SP. Prevention of early-onset neonatal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986; 314:1665-9.
19. Dillon HC, Khare S, Gray BM. Group B streptococcal carriage and disease: A 6-year prospective study. J Pediatr 1987;110:31-6.
20. Christensen KK, Dahlander K, Linden V, et al. Obstetrical care in future pregnancies after fetal loss in group B streptococcal septicemia. A prevention program based on bacteriological and immunological follow-up. Eur J Obstet Gynecol Reprod Biol 1981; 12:143-50.
21. Carstensen H, Christensen KK, Grennert L, et al. Early-onset neonatal group B streptococcal septicaemia in siblings. J Infect 1988;17:201-4.
22. Faxelius G, Bremme K, Kvist-Christensen K, et al. Neonatal septicemia due to group B streptococci-perinatal risk factors and outcome of subsequent pregnancies. J Perinat Med 1988;16: 423-30.
23. Flidel-Rimon O, Galstyan S, Juster-Reicher A, et al. Limitations of the risk factor based approach in early neonatal sepsis evaluations. Acta Paediatr 2012;101:e540-4.
24. Heath PT, Balfour G, Weisner AM, et al.; PHLS Group B Streptococcus Working Group. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 2004;363: 292-4.
25. Hakansson S, Källén K, Bullarbo M, et al. Real-time PCR-assay in the delivery suite for determination of group B streptococcal colonization in a setting with risk-based antibiotic prophylaxis. J Matern Fetal Neonatal Med. 2014;27:328-32.
26. Easmon CS, Hastings MJ, Deeley J, et al. The effect of intrapartum chemoprophylaxis on the vertical transmission of group B streptococci. Br J Obstet Gynaecol 1983;90:633-5.
27. Yow MD, Mason EO, Leeds LJ, et al. Ampicillin prevents intrapartum transmission of group B streptococcus. JAMA 1979; 241:1245-7.
28. Tuppurainen N, Hallman M. Prevention of neonatal group B streptococcal disease: intrapartum detection and chemprophylaxis of heavily colonized parturients. Obstet Gynecol 1989;73:583-7.
29. Royal College of Obstetricians and Gynecologsts. The prevention of early-onset neonatal group B streptococcal disease. Green-top Guideline No. 36. London: RCOG; 2012 [http://www.rcog.org.uk/womens-health/clinical-guidance/prevention-early-onset-neonatalgroup-b-streptococcal-disease-green-].
30. Hakansson S, Axemo P, Bremme K, et al; Swedish Working Group For The Prevention of Perinatal Group B Streptococcal Infections. Group B streptococcal carriage in Sweden: A national study on risk factors for mother and infant colonisation. Acta Obstet Gynecol Scand 2008;87:50-8.
31. Steer PJ, Plumb J. Myth: Group B streptococcal infection in pregnancy: comprehended and conquered. Semin Fetal Neonatal Med 2011;16:254-8.
32. Akker-van Marle ME, Rijnders ME, Dommelen P, et al. Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease. BJOG 2005;112:820-6.
33. Schrag SJ, Zell ER, Lynfield R, et al.; Active Bacterial Core Surveillance Team. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002;347:233-9.
34. Gilbert R. Prenatal screening for group B streptococcal infection: gaps in the evidence. Int J Epidemiol 2004;33:2-8.
35. Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev 2013;1:CD007467.
36. Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics 2005;115:1240-6.
37. Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med 2009;360:2626-36.
38. Pulver LS, Hopfenbeck MM, Young PC, et al. Continued earlyonset group B streptococcal infections in the ear of intrapartum prophylaxis. J Perinatol 2009;29:20-5.
39. Agence Nationale d'Accréditation et d'évaluation en Santé. Antenatal prevention of the risk of early neonatal bacterial infection: Clinical pratice guidelines. September 2001:1-10. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/Antenatal-prevention.pdf [last accessed 14 Jan 2014].
40. Superior Health Council. Guidelines from the Belgian Health Council, 2003 (SHC 7721): Prevention of perinatal group B streptococcal infections. Brussels, Belgium: Service Public Federal Sante publique, Securite de la Cha?ne alimentaire et Environnement, 2003 (In English, in French, in Dutch).
41. Alós Cortés JI, Andreu Domingo A, Arribas Mir L, et al. Prevention of Neonatal Group B Sreptococcal Infection. Spanish Recommendations. Update 2012. SEIMC/SEGO/SEN/SEQ/SEMFYC Consensus Document. Enferm Infecc Microbiol Clin 2013;31:159-72.
42. Stan CM, Boulvain M, Bovier PA, et al. Choosing a strategy to prevent neonatal early-onset group B streptococcal sepsis: economic evaluation. BJOG 2001;108:840-7.
43. Neonatal group B streptococcus infections in France: incidence from 1997 to 2006 and current prevention practices in maternity wards. Bulletin Epidémiologique Hebdomadaire 2008;14-15:110-13.
44. Stray-Pedersen B, Bergan T, Hafstad A. Vaginal disinfection with chlorhexidine during childbirth. Int J Antimicrob Agents 1999;12: 245-51.
45. Stade BC, Shah V, Ohlsson A. Vaginal chlorhexidine during labor to prevent early-onset neonatal group B streptococcal infection. Cochrane Database Syst Rev 2004;3:CD003520.
46. Cutland CL, Madhi SA, Zell ER, et al.; PoPS Trial Team. Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: A randomised, controlled trial. Lancet 2009;374:1909-16.
47. Facchinetti F, Piccinini F, Mordini B, Volpe A. Chlorhexidine vaginal flushings versus systemic ampicillin in the prevention of vertical transmission of neonatal group B streptococcus, at term. J Matern Fetal Neonatal Med 2002;11:84-8.
48. Goldenberg RL, McClure EM, Saleem S, et al. Use of vaginally administered chlorhexidine during labor to improve pregnancy outcomes. Obstet Gynecol 2006;107:1139-46.
49. Poyart C, Reglier-Poupet H, Tazi A, et al. Invasive Group B streptococcal infections in infants, France. Emerg Infect Dis 2008; 14:1647-9.
50. Manning SD, Springman AC, Lehotzky E, et al. Multilocus sequence types associated with neonatal group B streptococcal sepsis and meningitis in Canada. J Clin Microbiol 2009;47: 1143-8.
51. Sorensen UB, Poulsen K, Ghezzo C, et al. Emergence and global dissemination of host-specific Streptococcus agalactiae clones. MBio 2010;1:1-9.
52. Bellais S, Six A, Fouet A, et al. Capsular switching in group B streptococcus CC17 hypervirulent clone: A future challenge for polysaccharide vaccine development. J Infect Dis 2012;206: 1745-52.
53. Lamy MC, Dramsi S, Billoet A, et al. Rapid detection of the ''highly virulent'' group B Streptococcus ST-17 clone. Microbes Infect 2006;8:1714-22.
54. Lartigue MF, Kostrzewa M, Salloum M, et al. Rapid detection of ''highly virulent'' Group B Streptococcus ST-17 and emerging ST-1 clones by MALDI-TOF mass spectrometry. J Microbiol Methods 2011;86:262-5.
55. Stoll BJ, Schuchat A. Maternal carriage of group B streptococci in developing countries. Pediatr Infect Dis J 1998;17:499-503.
56. Bergeron MG, Menard C, et al. Rapid detection of group B streptococci in pregnant women at delivery. N Engl J Med 2000; 343:175-9.
57. Dahesh S, Hensler ME, Van Sorge NM, et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 2008;52:2915-18.
58. Kimura K, Suzuki S, Wachino J, et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 2008;52:2890-7.
59. Melin P. Table 3O Resistance of Streptococcus agalactiae in Belgium. In: SBIMC-BVIKM ed. The Sanford guide to antimicrobial therapy, 23rd edition of the Belgian/Luxembourg Version 2012-2013. Brussels, Belgium: Societe Belge d'Infectiologie et de Microbiologie Clinique-Belgische Vereniging voor Infectiologie en Klinische Microbiologie; 2012:178-9.
60. Back EE, O'Grady EJ, Back JD. High rates of perinatal group B streptococcus clindamycin and erythromycin resistance in an upstate New York hospital. Antimicrob Agents Chemother 2012; 56:739-42.
61. Domelier AS, van der Mee-Marquet N, Arnault L, et al. Molecular characterization of erythromycin-resistant Streptococcus agalactiae strains. J Antimicrob Chemother 2008;62:1227-33.
62. Pinheiro S, Radhouani H, Coelho C, et al. Prevalence and mechanisms of erythromycin resistance in Streptococcus agalactiae from healthy pregnant women. Microb Drug Resist 2009;15:121-4.
63. Bergseng H, Afset JE, Radtke A, et al. Molecular and phenotypic characterization of invasive group B streptococcus strains from infants in Norway 2006-2007. Clin Microbiol Infect 2009;12: 1182-5 (Research note 1-4).
64. Tazi A, Morand PC, Réglier-Poupet H, et al. Invasive group B streptococcal infections in adults, France (2007-2010). Clin Microbiol Infect 2011;17:1587-9.
65. Imperi M, Gherardi G, Berardi A, et al. Invasive neonatal GBS infections from an area-based surveillance study in Italy. Clin Microbiol Infect 2011;17:1834-9.
66. de Azavedo JC, McGavin M, Duncan C, et al. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob Agents Chemother 2001;45:3504-8.
67. Desjardins M, Delgaty KL, Ramotar K, et al. Prevalence and mechanisms of erythromycin resistance in group A and group B Streptococcus: implications for reporting susceptibility results. J Clin Microbiol 2004;42:5620-3.
68. Gygax SE, Schuyler JA, Kimmel LE, et al. Erythromycin and clindamycin resistance in group B streptococcal clinical isolates. Antimicrob Agents Chemother 2006;50:1875-7.
69. Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008;299:2056-65.
70. Castor ML, Whitney CG, Como-Sabetti K, et al. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008;2008:1-5.
71. Janapatla RP, Ho YR, Yan JJ, et al. The prevalence of erythromycin resistance in group B streptococcal isolates at a University Hospital in Taiwan. Microb Drug Resis 2008;14:293-7.
72. Seo YS, Srinivasan U, Oh KY, et al. Changing molecular epidemiology of group B streptococcus in Korea. J Korean Med Sci 2010;25:817-23.
73. Granlund M, Axemo P, Bremme K, et al; Swedish Working Group for the Prevention of Perinatal Group B Streptococcal Infections. Antimicrobial resistance in colonizing group B Streptococci before the implementation of a Swedish intrapartum antibiotic prophylaxis program. Eur J Clin Microbiol Infect Dis 2010;29:1195-201.
74. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002;34:482-92.
75. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. http://www.eucast.org.
76. Gilbert GL, Isaacs D, Burgess MA, et al. Prevention of neonatal group B streptococcal sepsis: is routine antenatal screening appropriate. Aust N Z J Obstet Gynaecol 1995;35:120-126.
77. Yancey MK, Schuchat A, Brown LK, et al. The accuracy of late antenatal screening cultures in predicting genital group B streptococcal colonization at delivery. Obstet Gynecol 1996;88:811-15.
78. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Screening and treatment for Group B streptococcus in pregnancy. College Statement C-Obs 19. 2009 [cited 2010 Feb 17]. Available from: www.ranzcog.edu. Au/publications/statements/C-obs19.pdf
79. Melin P, Schmitz M, Tsobo C, et al. Rapid intrapartum test (Strep B OIA) and prenatal cultures for identification of group B streptococcal carriers at delivery: A prospective study. In American Society of Microbiology (Ed.) Program and Abstracts of the 40th Intersciences Conference on Antimicrobial Agents and Chemotherapy 2000 (p145 No 357 session 30). Washington, USA: American Society for Microbiology (ASM). http://hdl. handle.net/2268/36477
80. Davies HD, Miller MA, Faro S, et al. Multicenter study of a rapid molecular-based assay for the diagnosis of group B Streptococcus colonization in pregnant women. Clin Infect Dis 2004;39:1129-35.
81. Valkenburg-van den Berg AW, Houtman-Roelofsen RL, Oostvogel PM, et al. Timing of group B streptococcus screening in pregnancy: A systematic review. Gynecol Obstet Invest 2010;69:174-83.
82. El Helali N, Nguyen JC, Ly A, et al. Diagnostic accuracy of a rapid real-time polymerase chain reaction assay for universal intrapartum group B streptococcus screening. Clin Infect Dis 2009 Aug 1;49: 417-23.
83. Towers CV, Rumney PJ, Asrat T, et al. The accuracy of late third-trimester antenatal screening for group B streptococcus in predicting colonization at delivery. Am J Perinatol 2010;27: 785-90.
84. Church DL, Baxter H, Lloyd T, et al. Evaluation of the Xpert- group B streptococcus real-time polymerase chain reaction assay compared to StrepB Carrot Broth- for the rapid intrapartum detection of group B streptococcus colonization. Diagn Microbiol Infect Dis 2011;69:460-2.
85. de Tejada BM, Pfister RE, Renzi G, et al. Intrapartum Group B streptococcus detection by rapid polymerase chain reaction assay for the prevention of neonatal sepsis. Clin Microbiol Infect 2011; 17:1786-91.
86. Young BC, Dodge LE, Gupta M, et al. Evaluation of a rapid, real-time intrapartum group B streptococcus assay. Am J Obstet Gynecol 2011;205:372.e1-6.
87. Lin FY, Weisman LE, Azimi P, et al. Assessment of intrapartum antibiotic prophylaxis for the prevention of early-onset group B Streptococcal disease. Pediatr Infect Dis J 2011;30:759-63.
88. Badri MS, Zawaneh S, Cruz AC, et al. Rectal colonization with group B Streptococcus: relation to vaginal colonization of pregnant women. J Infect Dis 1977;135:308-12.
89. Dillon HC, Gray E, Pass MA, Gray BM. Anorectal and vaginal carriage of group B streptococci during pregnancy. J Infect Dis 1982;145:794-9.
90. Connelian M, Wallace EM. Prevention of perinatal group B streptococcal disease: screening practice in public hospitals in Victoria. MJA 2000;172:317-20.
91. Nys S, Vijgen S, Magerman K, Cartuyvels R. Comparison of Copan eSwab with the Copan Venturi Transystem for the quantitative survival of Escherichia coli, Streptococcus agalactiae and Candida albicans. Eur J Clin Microbiol Infect Dis 2010;29: 453-6.
92. Melin P, Dodemont M, Sarlet G, et al. Improvement of transport condition of swabs for group B streptococcal screening. In American Society of Microbiology, Program and Abstracts of the 53rd Intersciences Conference on Antimicrobial Agents and Chemotherapy 2013 (poster D1662). Washington, USA: American Society for Microbiology (ASM).
93. Philipson EH, Palermino DA, Robinson A. Enhanced antenatal detection of group B streptococcus colonization. Obstet Gynecol 1995;85:437-9.
94. Platt MW, McLaughlin JC, Gilson GJ, et al. Increased recovery of group B Streptococcus by the inclusion of rectal culturing and enrichment. Diagn Microbiol Infect Dis 1995;21:65-8.
95. Montague N, Cleary T, Martinez O, Procop G. Detection of group B streptococci in Lim broth by use of group B Streptococcus peptide nucleic acid fluorescent in situ hybridization and selective and nonselective agars. J Clin Microbiol 2008; 46:3470-2.
96. Sociedad Española de Obstetricia y Ginecologá. Sociedad Española de Neonatologá. Sociedad Española de Enfermedades Infecciosas y Microbiologá Cĺnica. Sociedad Española de Quimioterapia. Sociedad Española de Medicina Familiar y Comunitaria. 2003. Prevención de la infección perinatal por estreptococo del grupo B. Recomendaciones españolas revisadas. Enferm Infecc Microbiol Clin 2003;21:417-23.
97. El Helali N, Giovangrandi Y, Guyot K, et al. Cost and effectiveness of intrapartum group B streptococcus polymerase chain reaction screening for term deliveries. Obstet Gynecol 2012; 119:822-9.
98. Haberland CA, Benitz WE, Sanders GD, et al. Perinatal screening for group b streptococci: cost-benefit analysis of rapid polymerase chain reaction. Pediatrics 2002;110:471-80.
99. Baker CJ. Inadequacy of rapid immunoassays for intrapartum detection of group B streptococcal carriers. Obstet Gynecol 1996; 88:51-5.
100. Picard FJ, Bergeron MG. Laboratory detection of group B Streptococcus for prevention of perinatal disease. Eur J Clin Microbiol Infect Dis 2004;23:665-71.
101. Bergeron MG, Ke D, Ménard C, Picard FJ, et al. Rapid detection of group B streptococci in pregnant women at delivery. N Engl J Med 2000;343:175-9.
102. Bergeron MG, Danbing K. New DNA-based PCR approaches for rapid real-time detection and prevention of group B streptococcal infections in newborns and pregnant women. Reprod Medi Rev 2004;11:I 25-41.
103. Aziz N, Baron EJ, D'Souza H, et al. Comparison of rapid intrapartum screening methods for group B streptococcal vaginal colonization. J Matern Fetal Neonatal Med 2005;18:225-9.
104. Atkins KL, Atkinson RM, Shanks A, et al. Evaluation of polymerase chain reaction for group B streptococcus detection using an improved culture method. Obstet Gynecol 2006;108: 488-91.
105. Gavino M, Wang E. A comparison of a new rapid real-time polymerase chain reaction system to traditional culture in determining group B Streptococcus colonization. Am J Obstet Gynecol 2007;197:388 e1-4.
106. Edwards RK, Novak-Weekley SM, Koty PP, et al. Rapid group B streptococci screening using a real-time polymerase chain reaction assay. Obstet Gynecol 2008;111:1335-41.
107. Money D, Dobson S, Cole L, et al. An evaluation of a rapid real time polymerase chain reaction assay for detection of group B streptococcus as part of a neonatal group B streptococcus prevention strategy. J Obstet Gynaecol Can 2008;30:770-5.
108. Smith D, Perry JD, Laine L, et al. Comparison of BD GeneOhm real-time polymerase chain reaction with chromogenic and conventional culture methods for detection of group B Streptococcus in clinical samples. Diagn Microbiol Infect Dis 2008;61:369-72.
109. Alfa MJ, Sepehri S, De Gagne P, et al. Real-time PCR assay provides reliable assessment of intrapartum carriage of group B Streptococcus. J Clin Microbiol 2010;48:3095-9.
110. Park JS, Cho DH, Yang JH, et al. Usefulness of a rapid real-time PCR assay in prenatal screening for group B streptococcus colonization. Ann Lab Med 2013;33:39-44.
111. Abdelazim IA. Intrapartum polymerase chain reaction for detection of group B streptococcus colonisation. Aust N Z J Obstet Gynaecol 2013;53:236-42.
112. Daniels J, Gray J, Pattison H, et al. Intrapartum tests for group B streptococcus: Accuracy and acceptability of screening. BJOG 2011;118:257-65.
113. Kaambwa B, Bryan S, Gray J, et al. Cost-effectiveness of rapid tests and other existing strategies for screening and management of early-onset group B streptococcus during labor. Br J Obstet Gynecol 2010;117:1616-27.
114. Bourgeois-Nicolaos N, Cordier AG, Guillet-Caruba C, et al. Evaluation of the Cepheid Xpert GBS assay for rapid detection of group B Streptococci in amniotic fluids from pregnant women with premature rupture of membranes. J Clin Microbiol 2013;51: 1305-6.
115. Langhendries JP. Early bacterial colonisation of the intestine: why it matters? Arch Pediatr 2006;13:1526-34.
116. Romero R, Korzeniewski SJ. Are infants born by elective cesarean delivery without labor at risk for developing immune disorders later in life? Am J Obstet Gynecol 2013;208:243-6.
117. Lorquet S, Melin P, Minon JM, et al. Group B streptococcus in the antenatal clinic and in the delivery room: A matter of systematic attitude. J Gynecol Obstet Biol Reprod 2005;34:115-27.
118. Hakansson S, Källén K. Impact and risk factors for early-onset group B streptococcal morbidity: Analysis of a national, population-based cohort in Sweden 1997-2001. BJOG 2006; 113:1452-8.
119. Telford JL, Barocchi MA, Margarit I, et al. Pili in Gram-positive pathogens. Nature Rev Microbiol 2006;4:509-19.
120. Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: The group B streptococcus paradigm. J Infect Dis 2009;199:108-15.
121. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20.
122. Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labor: 7-year follow-up of the ORACLE II trial. Lancet 2008;372:1319-27.
123. Fossieck B, Parker RH. Neurotoxicity during intravenous infusion of penicillin. A review. J Clin Pharmacol 1974;14:504-12.
124. Bloom SL, Cox SM, Bawdon RE, Gilstrap LC. Ampicillin for neonatal group B streptococcal prophylaxis: how rapidly can bactericidal concentrations be achieved? Am J Obstet Gynecol 1996;175:974-6.
125. Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by betalactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005;24:649-53.
126. Colombo DF, Lew JL, Pedersen CA, et al. Optimal timing of ampicillin administration to pregnant women for establishing bactericidal levels in the prophylaxis of group B Streptococcus. Am J Obstet Gynecol 2006;194:466-70.
127. Bray RE, Boe RW, Johnson WL. Transfer of ampicillin into fetus and amniotic fluid from maternal plasma in late pregnancy. Am J Obstet Gynecol 1966;96:938-42.
128. Fiore Mitchell T, Pearlman MD, Chapman RL, et al. Maternal and transplacental pharmacokinetics of cefazolin. Obstet Gynecol 2001;98:1075-9.
129. Popovic J, Grujic Z, Sabo A. Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs non pregnant sectioned women. J Clin Pharm Ther 2007;32:595-602.
130. Allegaert K, Van Mieghem T, Verbesselt R, et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol 2009;200:170 e1-7.
131. de Cueto M, Sanchez MJ, Sampedro A, et al. Timing of intrapartum ampicillin and prevention of vertical transmission of group B Streptococcus. Obstet Gynecol 1998;91:112-14.
132. Lin FY, Brenner RA, Johnson YR, et al. The effectiveness of risk-based intrapartum chemoprophylaxis for the prevention of early-onset neonatal group B streptococcal disease. Am J Obstet Gynecol 2001;184:1204-10.
133. Illuzzi JL, Bracken MB. Duration of intrapartum prophylaxis for neonatal group B streptococcal disease: A systematic review. Obstet Gynecol 2006;108:1254-65.
134. Barber EL, Zhao G, Buhimschi IA, Illuzzi JL. Duration of intrapartum prophylaxis and concentration of penicillin G in fetal serum at delivery. Obstet Gynecol 2008;112:265-70.
135. Berardi A, Rossi C, Biasini A, et al. Efficacy of intrapartum prophylaxis less than 4 hours duration. J Matern Fetal Neonatal Med 2011;24:619-25.
136. Ramus R, McIntire D, Wendell GJ. Antibiotic chemoprophylaxis for group B strep is not necessary with elective cesarean section at term [Abstract]. Am J Obstet Gynecol 1999;180(Suppl):85.
137. Poncelet-Jasserand E, Forges F, Varlet M-N, et al. Reduction of the use of antimicrobial drugs following the rapid detection of Streptococcus agalactiae in the vagina at delivery by real-time PCR assay. BJOG 2013;120:1098-108.